ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

AI specialist Atomwise signs with Bridge Biotherapeutics

by Rick Mullin
March 15, 2020 | APPEARED IN VOLUME 98, ISSUE 10

 

Atomwise, a specialist in applying artificial intelligence (AI) to small-molecule drug discovery, will collaborate with South Korea’s Bridge Biotherapeutics on up to 13 molecules in multiple therapeutic areas. Atomwise will use its structure-based AI technology to initiate programs for Pellino E3 ubiquitin ligases and other targets nominated by Bridge. Atomwise will receive unspecified up-front payments, as well as milestone and royalty payments that could top $1 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment